Co-Authors
This is a "connection" page, showing publications co-authored by ALEXANDER LAZAR and NEETA SOMAIAH.
Connection Strength
2.721
-
Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel). 2024 Apr 27; 16(9).
Score: 0.239
-
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
Score: 0.236
-
Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas. Front Oncol. 2023; 13:1046442.
Score: 0.220
-
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
Score: 0.212
-
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.
Score: 0.157
-
Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud. 2018 04; 4(2).
Score: 0.157
-
Molecular profiling of sarcomas: new vistas for precision medicine. Virchows Arch. 2017 Aug; 471(2):243-255.
Score: 0.149
-
Targeted therapies for sarcomas: new roles for the pathologist. Histopathology. 2014 Jan; 64(1):119-33.
Score: 0.116
-
Patterns of Care and Outcomes of Patients with Small Gastrointestinal Stromal Tumors at a High-Volume Sarcoma Center. Ann Surg Oncol. 2024 Dec; 31(13):9258-9264.
Score: 0.061
-
Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma? Am J Clin Oncol. 2024 Sep 03.
Score: 0.061
-
Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors. 2024; 16:20363613241271669.
Score: 0.061
-
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel). 2024 May 01; 16(9).
Score: 0.060
-
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
Score: 0.056
-
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Res. 2023 03 15; 83(6):939-955.
Score: 0.055
-
The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.
Score: 0.054
-
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res. 2022 09 15; 28(18):4092-4104.
Score: 0.053
-
Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother. 2022 10 01; 45(8):374-378.
Score: 0.053
-
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer. 2022 09 15; 128(18):3383-3391.
Score: 0.053
-
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022 06 15; 13(1):3406.
Score: 0.052
-
Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer. 2022 06 15; 150(12):2012-2024.
Score: 0.051
-
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther. 2020 05; 19(5):1165-1172.
Score: 0.045
-
Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020 02 21; 11(1):1008.
Score: 0.045
-
The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol. 2019 Sep; 120(3):382-388.
Score: 0.043
-
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).
Score: 0.042
-
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018 Sep 24; 18(1):913.
Score: 0.041
-
Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol. 2018 Apr; 117(5):879-885.
Score: 0.039
-
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018; 7(2):e1385689.
Score: 0.038
-
Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep. 2017 09 19; 7(1):11836.
Score: 0.038
-
Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.
Score: 0.037
-
Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol. 2018 09; 4:1-6.
Score: 0.037
-
High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. Transl Oncol. 2017 Aug; 10(4):546-554.
Score: 0.037
-
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Lab Invest. 2016 08; 96(8):885-94.
Score: 0.035
-
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol. 2015 Apr; 28(4):587-95.
Score: 0.031
-
Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol. 2014 Jul; 21(7):2136-43.
Score: 0.030
-
Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel). 2013 May 10; 5(2):529-49.
Score: 0.028